Literature DB >> 19053154

New applications and developments in the use of multiplex ligation-dependent probe amplification.

Piotr Kozlowski1, Anna J Jasinska, David J Kwiatkowski.   

Abstract

Multiplex ligation-dependent probe amplification (MLPA) is a commonly used technique for determining relative DNA sequence dosage (or copy number) in a complex DNA sample. Originally MLPA was designed as a copy number analysis tool for detecting disease-causing genomic mutations and has been successfully applied in the testing and identification of hundreds of genomic mutations in numerous genes including DMD, BRCA1, NF1, and TSC2. More recently, several modifications of the original technique have been implemented. Arguably the most important enhancement of MLPA has been probe generation by chemical synthesis, enabling the facile creation of novel probe sets for any desired application. Other newer applications of MLPA include methylation status determination, copy number analysis in segmentally duplicated regions, expression profiling, and transgene genotyping. MLPA has a potential major role in the analysis of common copy number variation in genome-wide association analyses, which may be enhanced by future improvements to increase throughput and lower costs, such as array-MLPA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053154     DOI: 10.1002/elps.200800126

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  26 in total

1.  Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer.

Authors:  Reza R Serizawa; Ulrik Ralfkiaer; Christina Dahl; Gitte W Lam; Alastair B Hansen; Kenneth Steven; Thomas Horn; Per Guldberg
Journal:  J Mol Diagn       Date:  2010-04-22       Impact factor: 5.568

2.  Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

Authors:  Laura Thomas; Lan Kluwe; Nadia Chuzhanova; Victor Mautner; Meena Upadhyaya
Journal:  Neurogenetics       Date:  2010-04-01       Impact factor: 2.660

Review 3.  Molecular testing in melanoma.

Authors:  Melissa Ann Wilson; Katherine L Nathanson
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

4.  Design and generation of MLPA probe sets for combined copy number and small-mutation analysis of human genes: EGFR as an example.

Authors:  Malgorzata Marcinkowska; Kwok-Kin Wong; David J Kwiatkowski; Piotr Kozlowski
Journal:  ScientificWorldJournal       Date:  2010-10-12

Review 5.  Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma.

Authors:  Katherine L Nathanson
Journal:  Biochem Pharmacol       Date:  2010-04-20       Impact factor: 5.858

6.  Distinct Gene Profiles for Tumor and Non-Tumor Tissue in the Head and Neck: An Analytical Approach.

Authors:  Mei Lu; Josena K Stephen; Kang Mei Chen; Shaleta Havard; Maria J Worsham
Journal:  J Cancer Sci Ther       Date:  2011-12-07

Review 7.  Molecular genetic testing and the future of clinical genomics.

Authors:  Sara Huston Katsanis; Nicholas Katsanis
Journal:  Nat Rev Genet       Date:  2013-06       Impact factor: 53.242

8.  Copy number variation of microRNA genes in the human genome.

Authors:  Malgorzata Marcinkowska; Maciej Szymanski; Wlodzimierz J Krzyzosiak; Piotr Kozlowski
Journal:  BMC Genomics       Date:  2011-04-12       Impact factor: 3.969

9.  MLPAinter for MLPA interpretation: an integrated approach for the analysis, visualisation and data management of Multiplex Ligation-dependent Probe Amplification.

Authors:  Ronald van Eijk; Paul H C Eilers; Remco Natté; Anne-Marie Cleton-Jansen; Hans Morreau; Tom van Wezel; Jan Oosting
Journal:  BMC Bioinformatics       Date:  2010-01-29       Impact factor: 3.169

10.  Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues.

Authors:  Anna Sapino; Margherita Goia; Daniele Recupero; Caterina Marchiò
Journal:  Front Oncol       Date:  2013-05-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.